Chemical genetics approach to identify new small molecule modulators of cell growth by phenotypic screening of Saccharomyces cerevisiae strains with a library of morpholine-derived compounds by Trabocchi, A. et al.
Chemical genetics approach to identify new small molecule modulators of
cell growth by phenotypic screening of Saccharomyces cerevisiae strains
with a library of morpholine-derived compounds
Andrea Trabocchi,*a Irene Stefanini,b Manfredi Morvillo,a Leonardo Ciofi,a Duccio Cavalieri*b
and Antonio Guarnaa
aDepartment of Chemistry “Ugo Schiff”, University of Florence, Polo Scientifico e Tecnologico,
Via della Lastruccia 13, I-50019, Sesto F.no, Florence, Italy. E-mail: andrea.trabocchi@unifi.it;
Fax: +39 055 4573531;Tel: +39 055 4573507
bDepartment of Pharmacology “Mario Aiazzi Mancini”, University of Florence, Viale Pieraccini
6, 50139, Florence, Italy. E-mail: duccio.cavalieri@unifi.it; Fax: +39 055 4271280; Tel: +39
055 4271327
Abstract
A chemical genetics approach has been applied in the screening of yeast deletants strains
with a pool of morpholine-derived compounds in order to identify candidate small molecules
able to produce phenotypic effects on yeast cells. The analysis of the effects of structurally
diverse  molecules  towards  cell  growth  rate  in  both  exponential  and  stationary  phases
provides  a  tool  to  select  candidate  compounds  for  subsequent  assays  to  identify  new
chemical entities as chemical probes for drug discovery.
Introduction
A central challenge in chemical genetics is the mapping of “biological-activity space”, which
involves  analysing  both  protein  binding  and  phenotypic  responses  with  respect  to  small
molecules.1 A number of high-throughput phenotypic assays have been developed, including
assays that measure cell viability or proliferation.2 After collecting a large amount of data on
the ability of the members of a chemical library to bind to a set of proteins and affect a set of
phenotypes,  the  data  can  be  analysed  to  determine  the  relationship  between  chemical
structure and biological activity. Each compound can be assigned a vector that describes the
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quantitative level  of  binding to  each protein,  and the quantitative effect  this  has on each
phenotype. Saccharomyces cerevisiae is particularly suited for the high-throughput screening
of  new  chemical  entities  on  whole  cell  systems  due  to  key  features  connected  to  easy
manipulation and the versatility of its genome.3 The life cycle is particularly rapid,as it divides
in  about  two hours,  it  is  possible  to  manipulate  both  haploid  and diploid  yeast  systems.
Moreover, it shows high degree of conservation with human cells concerning main biological
processes.  Yeast  cells  can  be  used  first  of  all  to  identify  novel  compounds  showing  an
inhibitory effect  on  growth.  Afterwards,  functional  information about  the mode-of-action of
selected  compounds  can  be  obtained  from  scoring~5,000  viable  yeast  haploid  deletion
mutant strains for hypersensitivity or hyper-resistance to each specific drug, thus identifying
pathways that influence cellular response to the toxic compound.4 We recently turned our
attention  to  morpholine-containing  molecules,  as  the  relevance  of  such  heterocycle  in
medicinal  chemistry  is  remarkable,  being  present  in  several  bioactive  molecules,such  as
TACE  (TNF-a  converting  enzyme),  5  MMP (matrix  metalloproteinase),  and  TNF  (tumour
necrosis factor) inhibitors. 6 Accordingly, we reported on the diversity-oriented synthesis of
morpholine scaffolds taking advantage of a two steps process involving the combination of
amino  acid  derivatives  as  building  blocks.7 Also,  the  conformational  analysis  of  peptides
containing  morpholine-3-carboxylic  acid  (Mor)  suggested  this  molecule  to  act  as  an
unexplored proline surrogate.8 We applied the reactivity of some morpholine acetals to give
access to a library of morpholine-derived molecules, some of which also contained the 2,5-
diketopiperazine  nucleus,  which  in  turn  is  considered  a  privileged  scaffold  in  medicinal
chemistry owing to the wide number of bioactive natural products and drugs containing such
chemical  entity.9 The  library  of  new  chemical  entities  was  successively  applied  for  the
systematic exploration of yeast deletants, so as to classify deletants as a function of bioactive
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molecules. Accordingly, a scatter diagram plotting the effect of the molecules towards yeast
cell growth in both the exponential and stationary phases was assessed as a criterion for hit
selection. Further experiments allowed for subsequent selection of candidate compounds as
chemical probes to be applied in Systems Biology investigations of cell cycle mechanisms. 
Results and discussion
Chemistry Scaffolds I–III were considered for library generation. Scaffold I was obtained from
the  combination  of  di  methoxy  acetaldehyde  A  and  serine  or  L-threonine  derivatives
corresponding to building blocks B with R1 H or CH3, respectively (Scheme 1).10 Scaffold II
was obtained as a single stereoisomer in two steps from phenacylbromide C and threonine
derivative  B  consisting  of  a  coupling  in  N-methylpyrrolidone,  followed  by  cyclization  in
HCl/MeOH solution (see ESI data). Scaffold III embedding a bicyclic lactone was obtained
from aminoacetaldehyde dimethylacetal D and protected methyl threonate derivative E, as
reported.7  Starting  from  scaffolds  I–II,  a  library  of  compounds  embed-ding  2,5-
diketopiperazine,  2-oxopiperazine,  morpholine  and  1,4-dihydro-oxazine  heterocycles  was
generated (see Scheme 2 and Table S1 in ESI data for the complete Chart of compounds).
Compounds 4 and 6–10 were obtained from a two-steps process consisting of a coupling with
Fmoc-aa-Cl,  followed  by  Fmoc  deprotection  with  concomitant  formation  of  the  2,5-
diketopiperazine  ring.  Library  members  11–26  were  obtained  by  a  three-steps  one-pot
process consisting of 1) coupling of Fmoc-aa-Cl, 2) 1,4-dihydro-oxazine formation through
acid-mediated double bond formation, 3) 2,5-diketopiperazine ring formation by treatment with
30% piperidine as the Fmoc-deprotecting agent. The stepwise process consisting of an acid–
base workup after amino acid coupling allowed for the achievement of the bicyclic structure of
compounds  27–35  embedding  2-oxo-piperazine  and  oxazolidine  rings,  as  evinced  by
crystallographic data obtained for compound 34 (Fig. 1). The absence of 2,6-lutidine in the
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mixture,and the use of catalytic quantities of p-TSA in the second step were found beneficial
for the intermediate oxonium species to undergo an attack by the urethane nitrogen atom,
followed  by  a  rearrangement  towards  the  new  bicyclic  species.  Finally,  compound5was
considered in the library to assess the effects of a monocyclic intermediate with respect to
parent  bicyclic scaffolds.  Bicyclic lactone III  was employed for the construction of bicyclic
diketopiperazines 36–42 by coupling with bromoacetyl bromide(scaffold IV) or Fmoc-L-Pro-Cl
(scaffold V), and subsequent cyclization by treatment with selected primary amines or 30%
piperidine  as  the  Fmoc-deprotection  agent  (Scheme  3  and  TableS1  in  ESI  data).  The
hydroxymethyl  group  was  successively  processed  to  access  further  chemical  diversity.
Esterification of compounds 43–44, coming from scaffold V and IV respectively, with myristic
acid allowed for the generation of lipidated scaffolds to envisage potential interactions across
the  cell  membrane.  Also,  acid-catalyzed  processes  were  applied  to  myristoyl-L-proline-
derived compound 43 to obtain the corresponding 1,4-dihydro-oxazine derivative 45, and to
41–42 possessing the free hydroxy group to obtain the corresponding polycyclic scaffolds 47
and 46, respectively. 
Biology
The effects of 48 compounds were initially tested at 0.3 mM concentration on the BY4742
wild-type strain (Fig. 2a). Compounds responsible for the variation in cell  generation time,
which is the time interval required for a yeast cell  to divide, or of the O.D.650 value of the
stationary phase (O.D.st),  or  both, were selected for further  characterization. Most  of  the
molecules induced higher fitness on the wild-type strain, as shown by higher O.D.st and lower
GenT values, some of which inducing a more intense effect, e.g. 11, 13, 27, and 28. Only two
molecules,5and44, induced a decrease in the yeast fitness, assumed from both an O.D.st
decrease and a GenT increase. Other molecules, such as6,45and47, induced an O.D. st and
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GenT increase. In this case the increase of the O.D.st  can be ascribed to an increase of the
cellular volume, rather than to an increase in cell concentration, which should be associated
to  a  lower  GenT.  The  screening  on  the  wild-type  strain  allowed  for  the  selection  of  21
molecules inducing an O.D.st and/or GenT variation in absolute value higher than 10% or
others interesting effects (e.g. decrease of the yeast fitness). Some structural determinants
could be drawn for this first run of screening (see Table S1 in ESI file). Activity of compound 3
with respect to 2 highlighted the importance of the phenyl substituent at position 6 of the
morpholine  ring.  The  role  of  such  substituent  was  also  evident  by  comparing  L-leucine-
derived  hit  compound11with  respect  to  the  correspondingscaffold15lacking  of  the  phenyl
substituent. Remarkable activity of 5 with respect to parent bicyclic compound26emphasized
the importance of the 1,4-dihydro-oxazine ring with respect to the 2,5-diketopiperazine moiety,
and also  the  influential  role  of  the bulky  hydrophobic  Fmoc group.  The effect  of  42  with
respect to 36–40 showed the role of the p-methoxybenzyl group in the pool of com-pounds
originated from scaffold IV. Activity of compound44alsoput evidence on the role of lipidated
derivatives.  Such  compounds  were  thus  tested  for  effects  on  the  BY4742Δerg6,
BY4742Δsnq2 and BY4742Δpdr3 deletion strains bearing deficiencies in genes involved in
cell wall and MDR (Multi Drug Resistance) (Fig. 2B, 2c, and 2d). The use of a pool of strains
bearing  deletions  of  genes  involved  in  membrane  assembly  or  function  enables  the
identification of effects that could be concealed by membrane permeation incapability of the
molecule.  Moreover  it  allows  for  the  identification  of  pathways  that  influence  the  cellular
response to tested compounds (if the deleted gene is the gene coding the compound target,
the compound stops inducing the effects showed on the wild-type strain). Erg6p is a methyl
transferase, having a downstream role in the ergosterol biosynthesis with respect to one of
the morpholine target (Erg24p), and upstream with respect to the other morpholine target
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(Erg2p);  Snq2p  is  drug-efflux  pump  ABC  (ATP-Binding  Cassette)  transporter  conferring
resistance  to  drugs  and  oxygen  radicals;  Pdr3  is  a  transcriptional  co-activator  of  genes
encoding ABC transporters. Compound 3 induced dramatic effects on GenT of BY4742Δsnq2
and BY4742Δpdr3 (102.6% and 157.6%, respectively),  with a proportional  O.D.st increase
(3.4%  and  9.2%,  respectively),  whereas  it  induced  an  opposite  effect  on  the
BY4742Derg6strain  (Gent  -23.7%,  O.D.st  -6.1%).These  results  allowed  us  to  hypothesize
that3targets the ergosterol biosynthesis pathway downstream Erg6p. Much more intense was
the effect of molecule 5 on GenT of the deletant strain BY4742Δerg6 (921.5%). Interestingly,
several molecules showed opposite effects on deletant strains with respect to the wild-type
strain. Specifically, molecules 3, 6 and 35, inducing an O.D.st decrease in the wild-type strain,
induced the same, though weaker, effect on BY4742Δerg6 strain, and an opposite effect on
BY4742Δpdr3 and BY4742Δsnq2 strains, showing that the activity of the molecule is affected
by cell MDR (Multi Drug Resistance) systems. Compound 42, inducing an O.D. st decrease in
the BY4742 (-10.8%), had opposite skills on BY4742Δerg6 and BY4742Δpdr3 strains (20.1%
and 4.2%, respectively), indicating a possible transcriptional target. Molecule 5 induced an
O.D.st decrease  on  wild-type,  Δerg6 and  Δpdr3 strains  (-28.1%,  -10.5%  and  -8.5%,
respectively), but induced an increase on the Δsnq2 strain (5.8%). Compound 29 induced an
O.D.st increase on every deletant strain, differently from the effect on the wild-type strain. The
myristoylated  compound  44  induced  a  O.D.st decrease  in  all  the  tested  strains,  with  the
greatest effect on the BY4742Δpdr3 strain.The eight molecules (3, 5, 6, 28, 29, 35, 42, and
44) inducing O.D.st and/or GenT variations higher than 10% on at least two of the deletant
strains were tested for mitochondrial membrane potential activation (Fig. 3) and peroxisomal
proliferation (Fig.  4).  Mitochondrial  membrane activation and peroxisomal  proliferation are
indicators of the metabolic state of the cell,disclosing respiratory and fatty acid metabolism,
6
125
130
135
140
145
respectively. The variation in mitochondrial membrane potential is also caused by ion-channel
permeability and drug binding.11 Peroxisomes are organelles containing enzymes for the b-
oxidation  of  fatty  acids,can  be  involved  in  inactivation  of  toxic  substrates  (H2O2-based
respiration), in the synthesis of ether phospholipids (in mammals) and in the breakdown of
purines and amino acids.12 Moreover, the peroxisome function and assembly are controlled by
ABC proteins.13 The mitochondrial activation skill of each molecule was assessed in various
metabolic  conditions,  growing  cells  in  YP  supplemented  with  different  carbon  sources:
glucose and galactose (both fermentable and non fermentable carbon source), glycerol (non
fermentable) and oleate (fatty acid, b-oxidable by peroxisomes). All the selected molecules
induced lower percentage of mitochondrial  activation with respect to the control  treatment
(with DMSO), in particular the 3 molecule induced the lowest mitochondrial activation in all the
media assayed (Fig. 3). The only molecule inducing an increase in mitochondrial activation
was42in YPGal. The peroxisomal proliferation was unaltered in every treatment but in the
treatment with3and5molecules, in which it was decreased in a statistically significant level.
Interestingly,the molecule3induced an apparent wall modification on the strain BY4742Δerg6,
as observable by decreased Calcofluor White staining, confirming the hypothesis that this
molecule target is the ergosterol biosynthesis pathway (Fig. 5). Our results indicate that the
molecules  3  and  5  show  bright  activities.  Compound3,  inducing  the  lowest  peroxisomal
proliferation  and a  growth  increase in  Δsnq2  and  Δpdr3 strains,  is  a  promising  powerful
instrument  to  gain  further  insight  into  the  drug  resistance  mechanism and  acquisition  in
mammal and yeast cells. On the other hand, compound5, showing killer activity only toward
wild-type  and  Δerg6  strains,  may  be  further  explored  as  a  suitable  chemical  probe  for
assessing  the  mechanisms  underlying  the  multidrug  resistance  of  pathogenic  cells  with
respect to normal cells. The likely function of molecule 5 on the cells is a starvation induction,
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induced by respiration and b-oxidation decrease (observable by the mitochondrial activity and
peroxisomal proliferation reduction).
Conclusions
The process of generating libraries of new chemical entities carrier of chemical diversity, and
the screening towards suitable living systems such as Saccharomyces cerevisiae through a
chemical  genetics  approach  is  a  promising  and  powerful  tool  to  identify  candidate  small
molecules for drug discovery purposes. Accordingly, the graphical inspection of the effects of
structurally diverse molecules towards cell  growth rate in both exponential  and stationary
phases through scatter plots  provides a rapid and efficient  tool  to evaluate the effects of
library  members  with  respect  to  different  yeast  deletant  strains,  thus  enabling  the
classification of phenotype responses as a function of the chemotype, and to provide new
chemical tools for Systems Biology. 
Experimental
General procedure A for the synthesis of compounds 4,6–10 from scaffold I 
Morpholine acetal I (1 eq) was dissolved in toluene(10 mL mmol-1), then 2,6-lutidine (2 eq)
and Fmoc-aa-Cl (1 eq) were sequentially added. The reaction mixture was brought to60◦C
and stirred for  2 h.  The reaction mixture was brought  back at  r.t.  and 30% diethylamine
solution in CH3CN (5 mL mmol-1) was added. The reaction mixture was stirred for 2 h at r.t.,
then diluted with EtOAc (40 mL mmol-1), washed with 5% NaHCO3and brine. The organic
layers were dried over anhydrous Na2SO4, filtered and evaporated. A dark brown oil  was
obtained  and  purified  by  flash  chromatograhy  (EtOAc–petroleum ether  2  :  1),  giving  the
title2,5-diketopiperazine compounds. See ESI file for characterization data. 
General procedure B for the synthesis of compounds 11–26 from scaffold I or II 
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Morpholine acetal I or II(1 eq) was dissolved in toluene(10 mL mmol-1), then 2,6-lutidine (2
eq) and Fmoc-aa-Cl (1 eq) were sequentially added. The reaction mixture was brought to60◦C
and stirred for 2 h, then allowed to return at r.t. Additional toluene (5 ml mmol-1) and p-toluene
sulfonic acid monohydrate (5 eq) were added, then the mixture was placed in a single-necked
round-bottomed flask equipped with a reflux condenser and a dropping funnel containing 4 A
molecular sieves and it was refluxed for 2 h. The reaction mixture was brought back at r.t.̊
and30% diethylamine solution in CH3CN (5 mL mmol-1) was added. The reaction mixture
was stirred for 2 h at r.t., then diluted with EtOAc (40 mL mmol-1), washed with 5% NaHCO 3
and brine. The organic layers were dried over anhydrous Na2SO4, filtered and evaporated. A
dark brown oil was obtained and purified by flash chromatography (EtOAc–petroleum ether
2 : 1), giving the title2,5-diketopiperazine compounds. See ESI file for characterization data. 
General procedure C for the synthesis of compounds 27–35 from scaffold I 
Morpholine  acetal  I  (1  eq)  was dissolved in  anhydrous CH2Cl2 (4  mL mmol-1),  then 2,6-
lutidine (2 eq) and Fmoc-aa-Cl (1 eq) were sequentially added. The reaction mixture was
brought to 60◦C and stirred for 2 h under a nitrogen atmosphere. The reaction mixture was
then diluted with CH2Cl2 and sequentially washed with 5% HCl, 5% NaHCO3 and brine. The
organic layers were dried overNa2SO4, filtered and evaporated to give a brownish foam. The
crude product  was then dissolved in  toluene  (5  mL mmol-1)  and  p-toluene sulfonic  acid
monohydrate (1 eq) was added. The reaction mixture was placed in a single-necked round-
bottomed flask  equipped with  a  reflux  condenser  and a  dropping funnel  containing  4  A  ̊
molecular sieves and refluxed for 2 h, then it was allowed to return to r.t. EtOAc was added,
and the organic solution was washed with 5% NaHCO3 and brine. The organic layers were
dried over anhydrous Na2SO4, filtered and evaporated to give a dark brown oil. The crude
product was dissolved in 30% diethylamine in CH3CN (5 mL mmol-1) and allowed to react for
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2 h at r.t. The reaction mixture was then evaporated to obtain a pale brown solid, which was
purified by flash chromatography (EtOAc-petroleum ether 3 : 1), to give the title bicyclic 2-
oxopiperazine compounds as dark orange oils. See ESI file for characterization data.
General procedure D for the synthesis of compounds 36–40 and 42 from scaffold IV
Bromoacetyl-lactoneIV7was dissolved in MeOH (1 mL mmol-1),then selected primary amine
(5  eq)  and  Et3N  (5  eq)  were  added,and  the  mixture  was  left  reacting  in  a  microwave
synthesizer at100◦C for 20 min. The mixture was then diluted with CH2Cl2and eluted through
Amberlist A-21 Amberlist 15 resins. After solvent evaporation, pure compound was obtained
without further chromatographic purification. See ESI file for characterization data.
Yeast strains and media
The wild-type BY4742 (MATahis3 leu2 lys2 ura3) strain was used. The deletion strains used
were  BY4742Dsnq2(MATahis3leu2  lys2  ura3  snq2::kanMX),  BY4742Dpdr3(MATahis3
leu2lys2 ura3 pdr3::kanMX4), and BY4742Derg6(MATahis3 leu2lys2 ura3 erg6::kanMX4). For
growth inhibition tests, yeast cells were inoculated at 1¥105cell/ml in YPD medium (Yeast
Peptone Dextrose, yeast extract 1% (w/v), peptone 2% (w/v) supplemented with 2% glucose).
BY4742FOX3-GFP(MATa his3  leu2 met15ura3 YIL160c-GFP),  a  strain  bearing  the  fusion
product  GFP-FOX3,  3-ketoacyl-CoA thiolase,  having peroxisomal  localization)was used to
follow  peroxisomal  proliferation.  For  mitochondrial  membrane  activation  and  peroxisomal
proliferation  assays  YP  added  with  various  Carbon  sources  was  used:  2%  Glucsose
(YPD),2% Galactose (YPGal), 2% Glycerol (YPGly) and 0.2% Oleate (YPO, supplemented
with 0.2% Tween80 to emulsify oleate).
Biological assays
BY4742 strain was grown in YPD. The cultures was dispensed at equal volume onto 96-well
plates, each well containing a different compound at a concentration of 0.3 mM. The assay
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plates were incubated at 28◦C with shaking, and yeast growth was scored by measurement of
O.D.650with a Victor high-throughput microplate spectrophotometer equipped with a 96-well
plate  reader  every  2  h  for  the  first  24  h,  and then once  a  day  for  4  days.  Compounds
responsible for the variation in cell generation time (the time interval required for a yeast cell
to divide), or of the O.D.650value of the stationary phase (O.D.st), or both, were selected for
further characterization. Cell generation time (GenT, the time interval required for a yeast cell
to divide) was calculated as D(t2-t1)/{3.3*[log10(O.D.t2/O.D.t1)]},  where t1 and t2 are time
points flanking the inflection point of the growth curves. The percent effect of each molecule
was calculated as a function of the GenT or O.D.st value of treated cells and the GenT or
O.D.st of untreated cells. The effects on deletant stains was assayed for selected compounds.
Deletion strains BY4742Δsnq2, BY4742Δpdr3, and BY4742Δerg6 were treated conformingly
with the wild-type strain treatment, with 0.3 mM molecules. Compounds responsible for the
variation in deletant strain cells generation time, or of the O.D.st value, or both, were selected
for mitochondrial and peroxisomal investigations.
Fluorescence microscopy 
Effects at  the mitochondrial  level  of  selected compounds were observed by mitochondrial
membrane potential investigation. Effects at the peroxisomal level were investigated by GFP-
FOX3microscopic observation. After 4 h of treatment with selected compounds at 0.3 mM
concentration, or without them as a control, cultured cells were dissolved at 1¥106cells ml-1in
10 mM HEPES buffer, pH 7.4, containing 5% glucose. Rhodamine B hexylester was added to
a final concentration of 100 nM. After 15–30 min of incubation, the mitochondrial membrane
potential was visualized by fluorescence microscopy (excitation at 555 nm,green/emission at
579 nm, red). Each aliquot was treated with Calcofluor White (M2R) (Blue) to evidence the
cell  wall  in  orderto  count  total  cells.  Mitochondrial  membrane  potential  activation  was
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calculated as  percentage of  red-fluorescent  cells  (rhodamine B hexyl  ester-labelled  cells)
toward total blue-cells (Calcofluor White-labelled cells) of the same treated culture.
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Schemes
Scheme 1 Generation of morpholine scaffolds through three different pathways.
15
Scheme 2 Library members from scaffolds I–II.
16
Scheme 3 Library members from scaffold III.
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Figures 
Fig. 1 X-Ray structure of 34.
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Fig. 2 Graphical representation of the effects of the molecules a) on the BY4742 wild-type
strain  b)  on  the  BY4742Derg6  strain  c)  on  the  BY4742Dsnq2  strain  and  d)  on  the
BY4742Dpdr3 strain. Percent values on both axes are referred to the untreated strain.
19
Fig. 3 Mitochondrial activation induced by the selected molecules on theBY4742 strain grown
in various media. Values indicate the mean of three measurements, error bars indicate the
corresponding standard deviations values. Student’s t  test  was used to evaluate the data
significance, *, p<0.05; **, p<0.01.
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Fig. 4 Peroxisomal proliferation induced by the treatment of the strainBY4742-GFP/FOX3 with
the selected molecules. Values indicate the mean of tree measurements, error bars indicate
the corresponding standard deviations values. Student’s t test was used to evaluate the data
significance,*, p<0.05; **, p<0.01
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Fig.  5  Microscopic  observation  of  the  effects  of  eight  selected  molecules  on  the
BY4742FOX3-GFP strain grown in YPO (0.2%). a) cells wall stained with Calcofluor White b)
mitochondrial  membrane  potential  activation  visualized  with  Rhodamine  B  hexyl  ester  c)
peroxisomes individuated by fusion product FOX3-GFP expression, a 3-ketoacyl-CoAthiolase,
having peroxisomal localization.
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